US20140161878A1 - Multi-nutrient supplement and uses thereof - Google Patents

Multi-nutrient supplement and uses thereof Download PDF

Info

Publication number
US20140161878A1
US20140161878A1 US14/104,940 US201314104940A US2014161878A1 US 20140161878 A1 US20140161878 A1 US 20140161878A1 US 201314104940 A US201314104940 A US 201314104940A US 2014161878 A1 US2014161878 A1 US 2014161878A1
Authority
US
United States
Prior art keywords
vitamin
source
composition
disease
potassium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/104,940
Inventor
Per-Arne Öckerman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sweet Wellness AB
Original Assignee
Sweet Wellness AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sweet Wellness AB filed Critical Sweet Wellness AB
Priority to US14/104,940 priority Critical patent/US20140161878A1/en
Publication of US20140161878A1 publication Critical patent/US20140161878A1/en
Priority to US16/389,326 priority patent/US11590190B2/en
Priority to US17/379,255 priority patent/US11963992B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/75Rutaceae (Rue family)
    • A61K36/752Citrus, e.g. lime, orange or lemon
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115Fatty acids or derivatives thereof; Fats or oils
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135Bacteria or derivatives thereof, e.g. probiotics
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15Vitamins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15Vitamins
    • A23L33/155Vitamins A or D
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16Inorganic salts, minerals or trace elements
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/175Amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/01Hydrocarbons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/01Hydrocarbons
    • A61K31/015Hydrocarbons carbocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07Retinol compounds, e.g. vitamin A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/14Quaternary ammonium compounds, e.g. edrophonium, choline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/194Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415Pyridoxine, i.e. Vitamin B6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51Thiamines, e.g. vitamin B1
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525Isoalloxazines, e.g. riboflavins, vitamin B2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/5939,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004Monosaccharides having only carbon, hydrogen and oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135Compounds containing heavy metals
    • A61K31/714Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/14Alkali metal chlorides; Alkaline earth metal chlorides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/18Iodine; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/30Zinc; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/32Manganese; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/34Copper; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/42Phosphorus; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/60Fish, e.g. seahorses; Fish eggs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747Lactobacilli, e.g. L. acidophilus or L. brevis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/45Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • Nutritional supplements available today are composed of ingredients that most often act against a particular condition, but not against a spectrum of conditions. For example, probiotics present a popular means for specifically balancing the intestinal flora and food digestion. There are no multi nutritional supplements on the market today, however, that comprise ingredients necessary for, e.g., simultaneously maintaining intestinal flora, supplying beneficial vitamins and trace elements, and combating diseases associated with oxidative stress, including cardiovascular disease (CVD).
  • CVD cardiovascular disease
  • compositions disclosed herein in various embodiments simultaneously maintain intestinal flora, supply beneficial vitamins and trace elements, and treat or prevent diseases associated with oxidative stress, including cardiovascular disease (CVD).
  • CVD cardiovascular disease
  • the compositions disclosed herein delay or prevent the onset of diseases associated with oxidative stress (i.e., primary prevention).
  • the compositions disclosed herein prevent the progression of diseases associated with oxidative stress by, e.g., relying on early detection of the disease(s) and applying an intervention such as administering a therapeutically effective amount of the compositions disclosed herein (i.e., secondary prevention).
  • the invention relates to a method for treating or prevent a disease and/or condition associated with oxidative stress (e.g., CVD) comprising administering to a human subject (e.g., a patient in need thereof) a therapeutically effective amount of a composition comprising vitamin A, vitamin B 1 , vitamin B 2 , vitamin B 3 , vitamin B 5 , vitamin B 6 , vitamin B 12 , vitamin C, vitamin D, vitamin E, vitamin K, folic acid, calcium source, potassium source, magnesium source, phosphate source, iodine, copper source, chromium source, manganese source, molybdenum source, selenium source, zinc source, one or more tocopherols or salts thereof, lycopene, one or more carotenoids, one or more flavonoids, biotin, inositol, choline, one or more amino acids, a probiotic composition comprising the powder of one or more dried fruits and pollen extract, and fish oil.
  • a probiotic composition compris
  • the invention relates to a method of delaying or preventing the onset of a disease and/or condition associated with oxidative stress (e.g., CVD) comprising administering to a human subject (e.g., a patient in need thereof) a therapeutically effective amount of a composition comprising vitamin A, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, folic acid, calcium source, potassium source, magnesium source, phosphate source, iodine, copper source, chromium source, manganese source, molybdenum source, selenium source, zinc source, lycopene, one or more carotenoids, one or more flavonoids, biotin, inositol, choline, one or more amino acids, a probiotic composition comprising the powder of one or more dried fruits and pollen extract, and fish oil.
  • a probiotic composition comprising the powder of one or more dried fruits and pollen extract, and fish oil.
  • composition comprising:
  • a range format should be interpreted in a flexible manner to include not only the numerical values explicitly recited as the limits of the range, but also to include all the individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub-range were explicitly recited.
  • a range of “about 0.1% to about 5%” or “about 0.1% to 5%” should be interpreted to include not just about 0.1% to about 5%, but also the individual values (e.g., 1%, 2%, 3%, and 4%) and the sub-ranges (e.g., 0.1% to 0.5%, 1.1% to 2.2%, 3.3% to 4.4%) within the indicated range.
  • the steps can be carried out in any order without departing from the principles of the invention, except when a temporal or operational sequence is explicitly recited. Furthermore, specified steps can be carried out concurrently unless explicit claim language recites that they be carried out separately. For example, a claimed step of doing X and a claimed step of doing Y can be conducted simultaneously within a single operation, and the resulting process will fall within the literal scope of the claimed process.
  • substantially refers to a majority of, or mostly, as in at least about 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, 99.99%, or at least about 99.999% or more.
  • ROS reactive oxygen species
  • ROS include not only radicals, but other related non-radical species that are formed during intracellular oxidation processes.
  • ROS include, but are not limited to, free radical species, such as superoxide radical anion (O 2 ⁇ ) and hydroxyl radical (.OH); and related non-radical species, such as peroxide (ROOR), hydrogen peroxide (H 2 O 2 ), singlet oxygen ( 1 O 2 ), and peroxynitrite (ONOO ⁇ ).
  • ROS reactive oxygen species
  • Free radicals have been implicated as being important in the pathogenesis in a wide range of diseases and pathological processes, including various forms of cancer, type-2 diabetes mellitus, atherosclerosis, chronic inflammatory conditions, ischemia/reperfusion injury, sepsis, and some neurodegenerative diseases. Droge W., Physiol. Rev. 82: 47-95 (2002). Oxidative stress is also thought to be involved in the development of many diseases including Parkinson's disease, Alzheimer's disease, heart failure, myocardial infarction, schizophrenia, bipolar disorder, fragile X syndrome, sickle cell disease, lichen planus, vitiligo, autism, and chronic fatigue syndrome. ROS can also be beneficial, however, as they are used by the immune system as a way to attack and kill pathogens.
  • Oxidative stress is thought to be linked to certain cardiovascular disease, since oxidation of low-density lipoproteins (LDL) in the vascular endothelium is a precursor to plaque formation. Oxidative stress also plays a role in the ischemic cascade due to oxygen reperfusion injury following hypoxia. This cascade includes both strokes and heart attacks. Oxidative stress has also been implicated in chronic fatigue syndrome. Oxidative stress also contributes to tissue injury following irradiation and hyperoxia, as well as in diabetes.
  • LDL low-density lipoproteins
  • Oxidative stress is likely to be involved in age-related development of cancer.
  • the reactive species produced in oxidative stress can cause direct damage to DNA and are therefore mutagenic.
  • Oxidative stress can also suppress apoptosis, promote proliferation, invasiveness, and metastasis.
  • Infection by Helicobacter pylori which increases the production of reactive oxygen and nitrogen species in human stomach is also thought to be important in the development of gastric cancer.
  • Oxidative stress is also thought to contribute to the aging process. There is good evidence to support this idea in model organisms such as Drosophila melanogaster and Caenorhabditis elegans . See, e.g., T. Finkel and N. Holbrook, Nature 408: 239-247 (2000).
  • Embodiments of the present invention are directed to compositions that have been shown to treat or prevent diseases associated with oxidative stress, including cardiovascular disease (CVD; e.g., atherosclerosis, heart infarct, and stroke).
  • CVD cardiovascular disease
  • These compositions comprise vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components, including biotin, inositol, and choline.
  • compositions comprise:
  • lactic acid bacteria include, but are not limited to, Lactobacillus. acidophilus, L. casei, L. plantarum, L. reuteri, L. helveticus, L. bulgaricus, L. brevis, L. therophilus, Bifidobacterium lactis, B. longum, B. breve, B. bifidum, B. animalis, Lactococcus lactis, Streptococcus thermophilus and cultures and combinations thereof.
  • any suitable form refers broadly to salts, hydrates, clathrates, D/L-forms (e.g., for amino acids); ⁇ / ⁇ forms (e.g., for polysaccharides), and diastereomers of the vitamins, minerals and trace elements, antioxidants, amino acids, and other components described herein as being present in the compositions of various embodiments of the present invention.
  • compositions of the various embodiments of the present invention comprising vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components, can be administered in any suitable dosage (e.g., the dosages provided in Table 1 herein) that is sufficient to treat or prevent diseases associated with oxidative stress. These compositions can also be administered over a period of time, with a frequency and duration, sufficient to treat or prevent diseases associated with oxidative stress.
  • compositions of the present invention comprise the components listed in Table 1 in the amounts shown. It should be understood, however, that those of ordinary skill in the art, with the benefit of the present disclosure, would be able to determine other amounts that would exert the beneficial effects of the compositions of the various embodiments of the present invention.
  • compositions are contemplated herein comprising 0.01-10 mg vitamin A (i.e., the range from Amount A); 2-30 mg vitamin B 1 (i.e., the range from Amount B); and 1-5 mg of vitamin B 2 (i.e., the range from Amount C).
  • the compositions of the various embodiments of the present invention comprising vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components
  • the amount of vitamin D the compositions of the various embodiments of the present invention comprising vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components can be about 0.0004 mg to about 4 mg; about 0.4 mg to about 4 mg; about 0.004 mg to about 0.04 mg; or about 0.01 to about 1 mg.
  • compositions of the various embodiments of the present invention comprising vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components, may be provided in any suitable form, including tablets, caplets, capsules, tablet-within-a-tablet, tablet/caplet/capsule-within-a-capsule (e.g., DuocapTM available from Capsugel Belgium NV), soft gel capsules, liquid caps (e.g., liquid filled hard capsules), sachets, powders, liquids, and the like.
  • suitable form including tablets, caplets, capsules, tablet-within-a-tablet, tablet/caplet/capsule-within-a-capsule (e.g., DuocapTM available from Capsugel Belgium NV), soft gel capsules, liquid caps (e.g., liquid filled hard capsules), sachets, powders, liquids, and the like.
  • unit dosages wherein the unit dosages comprises vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components in amounts sufficient to treat or prevent diseases associated with oxidative stress.
  • unit dosage refers to physically discrete units suitable as unit dosages, each unit comprising vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components in amounts (doses) sufficient to treat or prevent disease and/or condition associated with oxidative stress (e.g., CVD) or in amounts (doses) that are less than the amounts sufficient to treat or prevent a disease and/or condition associated with oxidative stress such that more than one unit dosage is necessary to provide the amounts sufficient to treat or prevent a disease and/or condition associated with oxidative stress.
  • dosage units are contemplated herein where a dosage unit provides 0.01 to 30 doses/dosage unit, e.g., 0.5 to 15 doses/dosage unit; or 1 to 5 doses/do
  • Dosage units include, but are not limited to, tablets, caplets, capsules, tablet-within-a-tablet, tablet/caplet/capsule-within-a-capsule (e.g., DuocapTM available from Capsugel Belgium NV), soft gel capsules, liquid caps (e.g., liquid filled hard capsules) sachets, powders, and the like.
  • a dosage unit can be, e.g., a single tablet, caplet, capsule, tablet-within-a-tablet, tablet/caplet/capsule-within-a-capsule, soft gel capsules, liquid caps (e.g., liquid filled hard capsules) sachets, powder, and the like, comprising vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components.
  • a dosage unit can comprise two or more tablets, caplets, capsules, tablet-within-a-tablet, tablet/caplet/capsule-within-a-capsule, soft gel capsules, liquid caps (e.g., liquid filled hard capsules) sachets, powder, and the like.
  • a dosage unit can be comprised of a tablet comprising every component but fish oil and probiotics, with the fish oil being in a capsule (or any suitable form), and the probiotics being in a powder (or any suitable form).
  • compositions of the present invention comprise vitamins, minerals and trace elements, antioxidants, amino acids, and other components, but lack probiotics and fish oil.
  • a dosage unit can comprise vitamins, minerals and trace elements, antioxidants, amino acids, and other components, but lack probiotics and fish oil.
  • the probiotics and/or fish oil can be provided separately.
  • the tablets and caplets contemplated herein may be any suitable tablets and caplets formed using compression methods know in the art, using various pharmaceutically acceptable excipients (e.g., microcrystalline cellulose, isomaltose, magnesium stearate, stearic acid, silicone dioxide, and mannitol).
  • the tablets can also comprise surface treatments including shellac and talcum powder.
  • a single tablet or caplet can contain the vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components in amounts sufficient to treat or prevent disease and/or condition associated with oxidative stress (e.g., CVD).
  • a plurality of tablets or caplets can contain one or more of the vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components, wherein the plurality of tablets or caplets (or combinations of tablets and caplets), together, comprise vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components in amounts sufficient to treat or prevent disease and/or condition associated with oxidative stress (e.g., CVD).
  • oxidative stress e.g., CVD
  • compositions of the various embodiments of the present invention comprising vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components, may be administered daily in any suitable interval (e.g., once daily, twice daily, and three times daily).
  • the compositions may be administered one or more time daily such that the daily amounts of the compositions are sufficient to treat or prevent disease and/or condition associated with oxidative stress (e.g., CVD).
  • oxidative stress e.g., CVD
  • 1-5 doses daily are contemplated.
  • kits comprising a unit dosage, wherein the unit dosage comprises vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components in amounts sufficient to treat or prevent disease and/or condition associated with oxidative stress (e.g., CVD).
  • the kit may comprise one or more suitable containers (e.g., a pouch, plastic bag, box, and the like).
  • the kit comprises one unit dosage in a suitable container.
  • the kit comprises more than one unit dosage (e.g., two, five, ten, fifteen, twenty-five, thirty or more unit dosages) in one or more suitable containers.
  • composition (A) was prepared by combining the component listed in Table 2, in the amounts listed, with microcrystalline cellulose, isomaltose, magnesium stearate, stearic acid, silicone dioxide, mannitol.
  • Six tablets can be prepared by compressing composition (A) using tableting techniques known in the art.
  • Vitamin A 2.4 mg Vitamin B 1 20 mg Vitamin B 2 20 mg Vitamin B 3 40 mg Vitamin B 5 48 mg Vitamin B 6 24 mg Vitamin B 12 0.04 mg Vitamin C 480 mg Vitamin D 0.02 mg Vitamin E 200 mg Vitamin K 0.12 mg Folic Acid 0.04 mg Calcium 320 mg Potassium 600 mg Magnesium 200 mg Phosphorus 240 mg Iodine 0.06 mg Copper 2 mg Chromium 0.16 mg Manganese 20 mg Molybdenum 0.06 mg Selenium 0.2 mg Zinc 20 mg Lycopene 12 mg Beta-carotene 12 mg Citrus flavonoids 100 mg Biotin 0.6 mg Inositol 20 mg Choline 120 mg
  • composition (A) A second composition was prepared that contained elevated vitamin D levels of 0.08 mg and cysteine, but was otherwise identical to composition (A).
  • This second composition, composition (B), was also tableted to provide six tablets.
  • compositions (B) was tested using a method identical to the method used to test composition (A).
  • the testing described in this non-limiting example is also described in the Journal of Orthomolecular Medicine 26: 159-162 (2011), the entirety of which is incorporated by reference as if fully set forth herein.
  • the objective of the tests described in this non-limiting example was to determine if the compositions of various embodiments of the present invention mitigates cardiovascular disease (CVD) risk factors as determined by pulse wave velocity (PWV) and augmentation index (AIX).
  • CVD cardiovascular disease
  • PWV pulse wave velocity
  • AIX augmentation index
  • each container containing:
  • Assays were made of PWV and AIX using arteriography. Assay values were given as a mean of three measurements at pre-treatment time and after two months of treatment. Values are given for PWV and AIX as determined by the arteriography.
  • Table 4 shows the results using the composition (B).
  • the male-to-female distribution was 51 females and 34 males.
  • the compositions (A) or (B) were taken orally during two months. Included were recommended dietary intakes (RDI) of all vitamins, minerals and trace elements, except iron, and higher doses of all B vitamins, vitamin C and E, selenium and magnesium.
  • RDI recommended dietary intakes
  • Measurement of cSBP, AIX, and PWV using artheriography measures the grade of arteriosclerosis and informs about three risk factors for heart infarct and stroke, namely, (i) stiffness in aorta, (ii) the function in smaller arteries, and (iii) central blood pressure. This method is considered to be the “gold standard” by European cardiovascular doctors.
  • compositions of various embodiments of the present invention produced highly significant improvements in aortic PWV (i.e., aortic artery stiffness) and AIX (i.e., peripheral artery stiffness and function) in two months.
  • aortic PWV i.e., aortic artery stiffness
  • AIX i.e., peripheral artery stiffness and function
  • Vitamin C and other antioxidants would counteract oxidation of cholesterol moieties (e.g., low-density lipoprotein cholesterol), but also diminish free radical activity, since oxidative stress is a well-known CVD risk factor.
  • subjects showing elevated levels of the three risk factors showed a decrease in the biological age of aorta with 29.7 years after ingesting the compositions of various embodiments of the present invention for two months.
  • Healthy subjects use the multi nutritional supplement at a lower dose compared to diagnosed subjects for preventing development of atherosclerosis and or other conditions and/or diseases caused by ROS and other environmental factors.
  • the results clearly show a rejuvenation process of the vessels, not only a way of reducing the rate of aging (anti-ageing), but actually a novel and inventive method to return to a lower biological age.
  • composition (B) described in Example 1 was prepared in tablet form using standard compression techniques according. Again, six tablets could be prepared from composition (B).
  • composition (A) was administered for two months using the same treatment regimen as in Example 1.
  • cysteine was used instead of N-acetyl cysteine, but otherwise in the same amount.
  • composition (A) could be combined with pollen extract, vitamin C, L-arginine, N-acetylcysteine, potassium, magnesium, and calcium to make a tablets or capsules that deliver, e.g., 1000 mg/day pollent extract, 2 g/day vitamin C, 2.25 g/day L-arginine, etc. Fish oil and the probiotic were kept separately.
  • composition (B) described in Example 1 was prepared in tablet form using standard compression techniques according. Again, six tablets could be prepared from composition (B).
  • composition (A) was administered for two months using the treatment regimen in Example 1. After two months, the regimen was amended to provide fewer composition (A) tablets, less than 1000 mg/day pollen extract, less than 2 g/day additional vitamin C, less than 2.25 g/day L-arginine, less than 400 mg/day N-acetylcysteine, less than 2 g/day fish oil, less than 367 mg/day potassium, less than 167 mg/day magnesium, less than 317 mg/day calcium, and less than 5 mL per day of the probiotic preparation, for an additional 34 months for a total of 36 months of treatment.
  • the present invention provides for the following exemplary embodiments, the numbering of which is not to be construed as designating levels of importance:
  • Embodiment 1 relates to a method for treating or prevent a disease and/or condition associated with oxidative stress (e.g., CVD) comprising administering to a human subject (e.g., a patient in need thereof) a therapeutically effective amount of a composition comprising vitamin A, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, folic acid, calcium source, potassium source, magnesium source, phosphate source, iodine, copper source, chromium source, manganese source, molybdenum source, selenium source, zinc source, one or more tocopherols or salts thereof, lycopene, one or more carotenoids, one or more flavonoids, biotin, inositol, choline, one or more amino acids, a probiotic composition comprising the powder of one or more dried fruits and pollen extract, and fish oil.
  • a probiotic composition comprising the powder of one or more dried
  • Embodiment 2 relates to the method of Embodiment 1, wherein the treating comprises preventing the progression of a disease and/or condition associated with oxidative stress.
  • Embodiment 3 relates to the method of Embodiments 1-2, wherein the disease and/or condition associated with oxidative stress is selected from the group consisting of cardiovascular disease, cancer, type-2 diabetes mellitus, atherosclerosis, chronic inflammatory conditions, ischemia/reperfusion injury, sepsis, neurodegenerative diseases, Parkinson's disease, Alzheimer's disease, heart failure, myocardial infarction, schizophrenia, bipolar disorder, fragile X syndrome, sickle cell disease, lichen planus, vitiligo, autism, chronic fatigue syndrome, and combinations thereof.
  • cardiovascular disease cardiovascular disease
  • cancer type-2 diabetes mellitus
  • atherosclerosis chronic inflammatory conditions
  • ischemia/reperfusion injury sepsis
  • neurodegenerative diseases Parkinson's disease
  • Alzheimer's disease Alzheimer's disease
  • heart failure myocardial infarction
  • schizophrenia bipolar disorder
  • fragile X syndrome fragile X syndrome
  • sickle cell disease lichen planus
  • vitiligo autism
  • chronic fatigue syndrome and combinations thereof.
  • Embodiment 4 relates to the method of Embodiment 1-3 wherein the disease and/or condition associated with oxidative stress is cardiovascular disease.
  • Embodiment 5 relates to the method of Embodiment 4, wherein the cardiovascular disease is at least one of atherosclerosis, heart infarct, and stroke.
  • Embodiment 6 relates to the method of Embodiments 1-5, wherein the composition comprises vitamin A (0.01-10 mg), vitamin B 1 (1-50 mg), vitamin B 2 (1-50 mg), vitamin B 3 (1-100 mg), vitamin B 5 (1-100 mg), vitamin B 6 (0.5-50 mg), vitamin B12 (0.0001-2 mg), vitamin C (0.1-1000 mg), vitamin D (0.0001-1 mg), vitamin E (1-500 mg), vitamin K (0.001-5 mg), folic acid (0.0001-5 mg), calcium source (0.1-1000 mg), potassium source (0.1-1000 mg), magnesium source (0.1-1000 mg), phosphate source (1-500 mg), iodine source (0.0001-5 mg), copper source (0.0001-10 mg), chromium source (0.0001-10 mg), manganese source (0.0001-50 mg), molybdenum source (0.0001-10 mg), selenium source (0.0001-10 mg), zinc source (0.001-50 mg), lycopene (0.0001-20 mg), one or more carotenoids (0.0001-20 mg), one or more flavonoids (1-
  • Embodiment 7 relates to the method of Embodiments 1-6, wherein the composition comprises an additional amount of vitamin D such that the total amount of vitamin D is 0.0004-4 mg vitamin D.
  • Embodiment 8 relates to the method of Embodiments 1-7, wherein the composition comprises an additional amount of at least one of vitamin C, a potassium source, a magnesium source, and a calcium source.
  • Embodiment 9 relates to the method of Embodiments 1-8, wherein the probiotic composition comprises lactic acid bacteria or cultures thereof (e.g., Lactococcis lactus culture, Lactobacillus rhamnosus culture, and combinations thereof), inulin, and dried powder of blueberries.
  • the probiotic composition comprises lactic acid bacteria or cultures thereof (e.g., Lactococcis lactus culture, Lactobacillus rhamnosus culture, and combinations thereof), inulin, and dried powder of blueberries.
  • Embodiment 10 relates to the method of Embodiments 1-9, wherein the composition comprises vitamin A, vitamin B 1 , vitamin B 2 , vitamin B 3 , vitamin B 5 , vitamin B 6 , vitamin B 12 , vitamin C, vitamin D, vitamin E, vitamin K, folic acid, potassium chloride, magnesium oxide, dicalcium phosphate, iodine, copper gluconate, chromium sulfate, manganese gluconate, potassium molybdate, selenomethionine, zinc lactate, d-alpha-tocopherol acetate, lycopene, beta-carotene, citrus flavonoids, L-cysteine or N-acetyl cysteine, L-arginine, a probiotic composition comprising dried powder of blueberries and pollen extract, d-biotin, inositol, choline-L-bitartarate, and fish oil.
  • the composition comprises vitamin A, vitamin B 1 , vitamin B 2
  • Embodiment 11 relates to a method of delaying or preventing the onset of a disease and/or condition associated with oxidative stress comprising administering to a human subject (e.g., a patient in need thereof) a therapeutically effective amount of a composition comprising vitamin A, vitamin B 1 , vitamin B 2 , vitamin B 3 , vitamin B 5 , vitamin B 6 , vitamin B 12 , vitamin C, vitamin D, vitamin E, vitamin K, folic acid, calcium source, potassium source, magnesium source, phosphate source, iodine, copper source, chromium source, manganese source, molybdenum source, selenium source, zinc source, lycopene, one or more carotenoids, one or more flavonoids, biotin, inositol, choline, one or more amino acids, a probiotic composition comprising the powder of one or more dried fruits and pollen extract, and fish oil.
  • a probiotic composition comprising the powder of one or more dried fruits and pollen extract
  • Embodiment 12 relates to a composition comprising:
  • Embodiment 13 relates to the composition of Embodiment 12, wherein the composition is in the form of a tablet, powder, liquid, capsule or combinations thereof.
  • Embodiment 14 relates to the composition of Embodiments 12-13, wherein components (i) and (iv) are comprised in the same dosage unit, separate from the probiotic composition and the fish oil.
  • Embodiment 15 relates to the composition of Embodiments 12-14, wherein the dosage unit is one or more tablets, caplets, capsules, tablet-within-a-tablet, tablet/caplet/capsule-within-a-capsule, soft gel capsules, liquid caps or sachets.
  • Embodiment 16 relates to the composition of Embodiments 12-15, wherein the composition comprises vitamin A (0.01-10 mg), vitamin B 1 (1-50 mg), vitamin B 2 (1-50 mg), vitamin B 3 (1-100 mg), vitamin B 5 (1-100 mg), vitamin B 6 (0.5-50 mg), vitamin B 12 (0.0001-2 mg), vitamin C (0.1-1000 mg), vitamin D (0.0001-1 mg), vitamin E (1-500 mg), vitamin K (0.001-5 mg), folic acid (0.0001-5 mg), calcium source (0.1-1000 mg), potassium source (0.1-1000 mg), magnesium source (0.1-1000 mg), phosphate source (1-500 mg), iodine source (0.0001-5 mg), copper source (0.0001-10 mg), chromium source (0.0001-10 mg), manganese source (0.0001-50 mg), molybdenum source (0.0001-10 mg), selenium source (0.0001-10 mg), zinc source (0.001-50 mg), lycopene (0.0001-20 mg), one or more carotenoids (0.0001-20 mg), one or more flavonoids (1-
  • Embodiment 17 relates to the composition of Embodiments 12-16, wherein the composition comprises an additional amount of vitamin D such that the total amount of vitamin D is 0.0004-4 mg vitamin D.
  • Embodiment 18 relates to the composition of Embodiments 12-17, wherein the composition comprises an additional amount of at least one of vitamin C, a potassium source, a magnesium source, and a calcium source.
  • Embodiment 19 relates to the composition of Embodiments 12-18, wherein the probiotic composition comprises lactic acid bacteria or cultures thereof (e.g., Lactococcis lactus culture, Lactobacillus rhamnosus culture, and combinations thereof), inulin, and dried powder of blueberries.
  • the probiotic composition comprises lactic acid bacteria or cultures thereof (e.g., Lactococcis lactus culture, Lactobacillus rhamnosus culture, and combinations thereof), inulin, and dried powder of blueberries.
  • Embodiment 20 relates to the composition of Embodiments 12-19, wherein the composition comprises vitamin A, vitamin B 1 , vitamin B 2 , vitamin B 3 , vitamin B 5 , vitamin B 6 , vitamin B 12 , vitamin C, vitamin D, vitamin E, vitamin K, folic acid, potassium chloride, magnesium oxide, dicalcium phosphate, iodine, copper gluconate, chromium sulfate, manganese gluconate, potassium molybdate, selenomethionine, zinc lactate, lycopene, beta-carotene, citrus flavonoids, L-cysteine or N-acetyl cysteine, L-arginine, a probiotic composition comprising dried powder of blueberries and pollen extract, d-biotin, inositol, choline-L-bitartarate, and fish oil.
  • the composition comprises vitamin A, vitamin B 1 , vitamin B 2 , vitamin B 3 , vitamin B 5 , vitamin B 6
  • Embodiment 21 relates to a kit comprising the composition of claims 13 - 20 in a suitable container.
  • Embodiment 22 relates to the kit of Embodiment 21, wherein the composition is comprised in a dosage unit.
  • Embodiment 23 relates to the kit of Embodiment 22, wherein the dosage unit is one or more tablets, caplets, capsules, tablet-within-a-tablet, tablet/caplet/capsule-within-a-capsule, soft gel capsules, liquid caps or sachets.
  • Embodiment 24 relates to the kit of Embodiments 21-23, wherein the composition comprises vitamin A, vitamin B 1 , vitamin B 2 , vitamin B 3 , vitamin B 5 , vitamin B 6 , vitamin B 12 , vitamin C, vitamin D, vitamin E, vitamin K, folic acid, potassium chloride, magnesium oxide, dicalcium phosphate, iodine, copper gluconate, chromium sulfate, manganese gluconate, potassium molybdate, selenomethionine, zinc lactate, lycopene, beta-carotene, citrus flavonoids, L-cysteine or N-acetyl cysteine, L-arginine, a probiotic composition comprising dried powder of blueberries and pollen extract, d-biotin, inositol, choline-L-bitartarate, and fish oil in amounts sufficient to treat or prevent a disease and/or condition associated with oxidative stress.
  • the composition comprises vitamin A, vitamin B

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Various embodiments of the invention relate to compositions comprising vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components and methods for using such compositions to treat or prevent diseases associated with oxidative stress, including cardiovascular disease.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application claims priority under 35 U.S.C. §119(e) from U.S. Provisional Appl. Ser. No. 61/736,215, filed Dec. 12, 2012, the entirety of which is incorporated by reference as if fully set forth herein.
  • BACKGROUND OF THE INVENTION
  • Nutritional supplements available today are composed of ingredients that most often act against a particular condition, but not against a spectrum of conditions. For example, probiotics present a popular means for specifically balancing the intestinal flora and food digestion. There are no multi nutritional supplements on the market today, however, that comprise ingredients necessary for, e.g., simultaneously maintaining intestinal flora, supplying beneficial vitamins and trace elements, and combating diseases associated with oxidative stress, including cardiovascular disease (CVD).
  • SUMMARY OF THE INVENTION
  • The compositions disclosed herein in various embodiments simultaneously maintain intestinal flora, supply beneficial vitamins and trace elements, and treat or prevent diseases associated with oxidative stress, including cardiovascular disease (CVD). In some embodiments, the compositions disclosed herein delay or prevent the onset of diseases associated with oxidative stress (i.e., primary prevention). In other embodiments, the compositions disclosed herein prevent the progression of diseases associated with oxidative stress by, e.g., relying on early detection of the disease(s) and applying an intervention such as administering a therapeutically effective amount of the compositions disclosed herein (i.e., secondary prevention).
  • In various embodiments, the invention relates to a method for treating or prevent a disease and/or condition associated with oxidative stress (e.g., CVD) comprising administering to a human subject (e.g., a patient in need thereof) a therapeutically effective amount of a composition comprising vitamin A, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, folic acid, calcium source, potassium source, magnesium source, phosphate source, iodine, copper source, chromium source, manganese source, molybdenum source, selenium source, zinc source, one or more tocopherols or salts thereof, lycopene, one or more carotenoids, one or more flavonoids, biotin, inositol, choline, one or more amino acids, a probiotic composition comprising the powder of one or more dried fruits and pollen extract, and fish oil.
  • In various other embodiments, the invention relates to a method of delaying or preventing the onset of a disease and/or condition associated with oxidative stress (e.g., CVD) comprising administering to a human subject (e.g., a patient in need thereof) a therapeutically effective amount of a composition comprising vitamin A, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, folic acid, calcium source, potassium source, magnesium source, phosphate source, iodine, copper source, chromium source, manganese source, molybdenum source, selenium source, zinc source, lycopene, one or more carotenoids, one or more flavonoids, biotin, inositol, choline, one or more amino acids, a probiotic composition comprising the powder of one or more dried fruits and pollen extract, and fish oil.
  • In still other embodiments, the invention relates to composition comprising:
      • (i) vitamin A, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, folic acid, calcium source, potassium source, magnesium source, phosphate source, iodine, copper source, chromium source, manganese source, molybdenum source, selenium source, zinc source, lycopene, one or more carotenoids, one or more flavonoids, biotin, inositol, choline, one or more amino acids,
      • (ii) a probiotic composition comprising the powder of one or more dried fruits and pollen extract,
      • (iii) fish oil, and
      • (iv) one or more pharmaceutically acceptable excipients.
    DETAILED DESCRIPTION OF THE INVENTION
  • Reference will now be made in detail to certain embodiments of the disclosed subject matter. While the disclosed subject matter will be described in conjunction with the enumerated claims, it will be understood that the exemplified subject matter is not intended to limit the claims to the disclosed subject matter.
  • Values expressed in a range format should be interpreted in a flexible manner to include not only the numerical values explicitly recited as the limits of the range, but also to include all the individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub-range were explicitly recited. For example, a range of “about 0.1% to about 5%” or “about 0.1% to 5%” should be interpreted to include not just about 0.1% to about 5%, but also the individual values (e.g., 1%, 2%, 3%, and 4%) and the sub-ranges (e.g., 0.1% to 0.5%, 1.1% to 2.2%, 3.3% to 4.4%) within the indicated range. The statement “about X to Y” has the same meaning as “about X to about Y,” unless indicated otherwise. Likewise, the statement “about X, Y, or about Z” has the same meaning as “about X, about Y, or about Z,” unless indicated otherwise.
  • In this document, the terms “a,” “an,” or “the” are used to include one or more than one unless the context clearly dictates otherwise. The term “or” is used to refer to a nonexclusive “or” unless otherwise indicated. In addition, it is to be understood that the phraseology or terminology employed herein, and not otherwise defined, is for the purpose of description only and not of limitation. Any use of section headings is intended to aid reading of the document and is not to be interpreted as limiting; information that is relevant to a section heading may occur within or outside of that particular section. Furthermore, all publications, patents, and patent documents referred to in this document are incorporated by reference herein in their entirety, as though individually incorporated by reference. In the event of inconsistent usages between this document and those documents so incorporated by reference, the usage in the incorporated reference should be considered supplementary to that of this document; for irreconcilable inconsistencies, the usage in this document controls.
  • In the methods described herein, the steps can be carried out in any order without departing from the principles of the invention, except when a temporal or operational sequence is explicitly recited. Furthermore, specified steps can be carried out concurrently unless explicit claim language recites that they be carried out separately. For example, a claimed step of doing X and a claimed step of doing Y can be conducted simultaneously within a single operation, and the resulting process will fall within the literal scope of the claimed process.
  • The term “about” as used herein can allow for a degree of variability in a value or range, for example, within 10%, within 5%, or within 1% of a stated value or of a stated limit of a range.
  • The term “substantially” as used herein refers to a majority of, or mostly, as in at least about 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, 99.99%, or at least about 99.999% or more.
  • The term “oxidative stress,” as used herein broadly refers to biological processes where harmful endogenous or exogenous oxidants, called reactive oxygen species (ROS), causes damage to biological systems and structures. ROS include not only radicals, but other related non-radical species that are formed during intracellular oxidation processes. ROS include, but are not limited to, free radical species, such as superoxide radical anion (O2 ) and hydroxyl radical (.OH); and related non-radical species, such as peroxide (ROOR), hydrogen peroxide (H2O2), singlet oxygen (1O2), and peroxynitrite (ONOO). These free radicals, and related species, participate in the regulation of signal transduction from membrane receptors, immunological and inflammatory responses, smooth muscle relaxation, redox homeostasis, apoptosis, and vascular tone, among others. Proper regulation of ROS provides protection against oxidative stress and provides important mediators in cellular processes. However, excessive production or improper clearance of ROS can result in damage to cellular constituents, such as proteins, DNA, and membrane lipids; dysfunction of intracellular signaling cascades; cytotoxicity; and enzyme inactivation.
  • Free radicals have been implicated as being important in the pathogenesis in a wide range of diseases and pathological processes, including various forms of cancer, type-2 diabetes mellitus, atherosclerosis, chronic inflammatory conditions, ischemia/reperfusion injury, sepsis, and some neurodegenerative diseases. Droge W., Physiol. Rev. 82: 47-95 (2002). Oxidative stress is also thought to be involved in the development of many diseases including Parkinson's disease, Alzheimer's disease, heart failure, myocardial infarction, schizophrenia, bipolar disorder, fragile X syndrome, sickle cell disease, lichen planus, vitiligo, autism, and chronic fatigue syndrome. ROS can also be beneficial, however, as they are used by the immune system as a way to attack and kill pathogens.
  • Oxidative stress is thought to be linked to certain cardiovascular disease, since oxidation of low-density lipoproteins (LDL) in the vascular endothelium is a precursor to plaque formation. Oxidative stress also plays a role in the ischemic cascade due to oxygen reperfusion injury following hypoxia. This cascade includes both strokes and heart attacks. Oxidative stress has also been implicated in chronic fatigue syndrome. Oxidative stress also contributes to tissue injury following irradiation and hyperoxia, as well as in diabetes.
  • Oxidative stress is likely to be involved in age-related development of cancer. The reactive species produced in oxidative stress can cause direct damage to DNA and are therefore mutagenic. Oxidative stress can also suppress apoptosis, promote proliferation, invasiveness, and metastasis. Infection by Helicobacter pylori which increases the production of reactive oxygen and nitrogen species in human stomach is also thought to be important in the development of gastric cancer.
  • Oxidative stress is also thought to contribute to the aging process. There is good evidence to support this idea in model organisms such as Drosophila melanogaster and Caenorhabditis elegans. See, e.g., T. Finkel and N. Holbrook, Nature 408: 239-247 (2000).
  • Embodiments of the present invention are directed to compositions that have been shown to treat or prevent diseases associated with oxidative stress, including cardiovascular disease (CVD; e.g., atherosclerosis, heart infarct, and stroke). These compositions comprise vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components, including biotin, inositol, and choline.
  • These compositions comprise:
      • vitamins, in any suitable form, including, but not limited to, at least one of vitamins A (retinyl or salts thereof, such as retinyl acetate), B1 (thiamine or salts thereof, such as thiamine hydrochloride), B2 (riboflavin), B3 (nicotinamide), B5 (calcium-d-pantothenate), B6 (pyridoxine or salts thereof, such as pyridoxine hydrochloride pyridoxine hydrochloride), B12 (cyanocobalamine), C, D (cholecalciferol), E (d-alpha-tocopherol acetate, but also beta-, gamma-, and delta-tocopherol or combinations thereof or salts thereof), and K (phylloquinone), and folic acid;
      • minerals and trace elements, in any suitable form, including, but not limited to, at least one of sources of calcium (e.g., dicalcium phosphate), potassium (e.g., in the form of potassium chloride), magnesium (e.g., in the form of magnesium oxide), phosphorus/phosphate (e.g., in the form of dicalcium phosphate), iodine, copper (e.g., in the form of copper gluconate), chromium (e.g., in the form of chromium sulfate), manganese (e.g., in the form of manganese gluconate), molybdenum (e.g., in the form of potassium molybdate), selenium (e.g. in the form of selenomethionine), and zinc (e.g., zinc lactate);
      • antioxidants, in any suitable form, including, but not limited to, at least one of tocotrienols or salts thereof, lycopene (e.g., in the form of lycopene extracted from tomatoes), carotenoids (e.g., beta-carotene), flavonoids (e.g., citrus flavonoids from citrus extract any suitable citrus source including, but not limited to orange, lemon, lime, and the like, and including hesperidin, quercetin, rutin, and tangeritin);
      • amino acids, in any suitable form (e.g., D or L form), including, but not limited to at least one of, arginine (e.g., L-arginine), cysteine (e.g., L-cysteine), and (e.g., N-acetyl cysteine (e.g., N-acetyl-L-cysteine);
      • probiotics, in any suitable form, including, but not limited to, at least one of a lactic acid bacteria and cultures thereof (e.g., Lactococcis lactus, Lactobacillus rhamnosus, cultures thereof and combinations thereof), fructans (e.g., inulin), dried fruit powders (e.g., powder of blueberries), dehydrated fruit or vegetable juice (e.g., beet root juice) or mixtures thereof, and pollen extract from, e.g., Royal Sport Pollen, which comprises pollen extract from Secale cereal, Zea mays, and Pinus sylvestris (available from Allergon AB, Sweden) in a probiotic composition/preparation comprising, e.g., lactic acid bacteria and cultures thereof (e.g., Lactococcis lactus, Lactobacillus rhamnosus, cultures thereof and combinations thereof), inulin, and dried powder of blueberries, where the probiotic composition/preparation is in any suitable form including powder form, suspension, emulsion, solution or reconstituted powder, reconstituted with water;
      • other components, in any suitable form, including, but not limited to, at least one of biotin (e.g., in the form of d-biotin), inositol, choline or salts thereof (e.g., in the form of choline-L-bitartarate), coenzymes (e.g., coenzyme Q10 in isolated form), Terminalia arjuna or an extract thereof, including the coenzymes (e.g., coenzyme Q10), glycosides, and tannins present therein; fish oil (e.g. fish oil containing omega-3 fatty acids with 30-80% purity), and vitamers (e.g., compounds that can be converted to the active form of a vitamin).
  • Other lactic acid bacteria include, but are not limited to, Lactobacillus. acidophilus, L. casei, L. plantarum, L. reuteri, L. helveticus, L. bulgaricus, L. brevis, L. therophilus, Bifidobacterium lactis, B. longum, B. breve, B. bifidum, B. animalis, Lactococcus lactis, Streptococcus thermophilus and cultures and combinations thereof. As used herein, the term “in any suitable form” refers broadly to salts, hydrates, clathrates, D/L-forms (e.g., for amino acids); α/β forms (e.g., for polysaccharides), and diastereomers of the vitamins, minerals and trace elements, antioxidants, amino acids, and other components described herein as being present in the compositions of various embodiments of the present invention.
  • The compositions of the various embodiments of the present invention comprising vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components, can be administered in any suitable dosage (e.g., the dosages provided in Table 1 herein) that is sufficient to treat or prevent diseases associated with oxidative stress. These compositions can also be administered over a period of time, with a frequency and duration, sufficient to treat or prevent diseases associated with oxidative stress. In one embodiment, compositions of the present invention comprise the components listed in Table 1 in the amounts shown. It should be understood, however, that those of ordinary skill in the art, with the benefit of the present disclosure, would be able to determine other amounts that would exert the beneficial effects of the compositions of the various embodiments of the present invention.
  • TABLE 1
    Specific
    Component Amount A Amount B Amount C Amounts
    Vitamin A 0.01-10 mg 0.01-10 mg 0.1-1 mg 0.4 mg
    Vitamin B1 1-50 mg 2-30 mg 1-5 mg 3.33 mg
    Vitamin B2 1-50 mg 2-30 mg 1-5 mg 3.33 mg
    Vitamin B3 1-100 mg 5-50 mg 2-10 mg 6.67 mg
    Vitamin B5 1-100 mg 5-50 mg 2-10 mg 8 mg
    Vitamin B6 0.5-50 mg 2-40 mg 1-5 mg 4 mg
    Vitamin B12 0.0001-2 mg 0.005-0.05 mg 0.001-0.01 mg 0.0067 mg
    Vitamin C 0.1-1000 mg 1-500 mg 200-500 mg 413 mg
    Vitamin D 0.0001-1 mg 0.1-1 mg 0.001-0.01 mg 0.0033 mg
    Vitamin E 1-500 mg 10-300 mg 20-50 mg 33.33 mg
    Vitamin K 0.001-5 mg 0.01-0.5 mg 0.005-0.05 mg 0.02 mg
    Folic Acid 0.0001-5 mg 0.005-0.5 mg 0.01-0.1 mg 0.067 mg
    Calcium 0.1-1000 mg 100-400 mg 50-200 mg 106 mg
    Potassium 0.1-1000 mg 100-800 mg 50-200 mg 161 mg
    Magnesium 0.1-1000 mg 50-300 mg 20-100 mg 61 mg
    Phosphorus 1-500 mg 100-300 mg 20-100 mg 40 mg
    Iodine 0.0001-5 mg 0.001-0.5 mg 0.005-0.05 mg 0.01 mg
    Copper 0.0001-10 mg 0.1-3 mg 0.01-0.5 mg 0.33 mg
    Chromium 0.0001-10 mg 0.001-1 mg 0.01-0.5 mg 0.027 mg
    Manganese 0.0001-50 mg 1-30 mg 1-5 mg 3.33 mg
    Molybdenum 0.0001-10 mg 0.001-1 mg 0.001-0.05 mg 0.01 mg
    Selenium 0.0001-10 mg 0.001-1 mg 0.001-0.05 mg 0.033 mg
    Zinc 0.001-50 mg 1-30 mg 1-5 mg 3.33 mg
    Lycopene 0.0001-20 mg 1-15 mg 1-5 mg 2 mg
    Beta-carotene 0.0001-20 mg 1-15 mg 1-5 mg 2 mg
    Citrus flavonoids 1-500 mg 10-150 mg 5-50 mg 16.67 mg
    Biotin 0.0001-20 mg 0.01-1 mg 0.01-0.5 mg 0.1 mg
    Inositol 0.001-100 mg 1-30 mg 1-5 mg 3.33 mg
    Choline 0.0001-500 mg 10-150 mg 5-20 mg 20 mg
    0.0001-20 mg
    Pollen extract 1-10,000 mg 100-5,000 mg 200-2000 mg 1000 mg/day
    L-arginine 0.0001-100 g 1-100 g 1-5 g 2.25 g/day
    Fish oil 0.0001-20 g 0.01-5 mg 1-5 g 2 g/day
    Probiotics 1-10 mL 1-5 mL 2-8 mL 5 mL
    Inulin 0.0001-100 mg 0.01-10 mg 1-20 mg
    Blue berries 0.0001-2000 mg 0.01-200 mg 10-500 mg
    (dried powder)
  • It is contemplated that in some embodiments, a range for a component from Amount A might be combined with a range of a different component from Amount B and a range of yet a different component from Amount C. For example, compositions are contemplated herein comprising 0.01-10 mg vitamin A (i.e., the range from Amount A); 2-30 mg vitamin B1 (i.e., the range from Amount B); and 1-5 mg of vitamin B2 (i.e., the range from Amount C).
  • In some embodiments, the compositions of the various embodiments of the present invention comprising vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components, can comprise elevated levels of vitamin D that are about four-fold the amount given in Table 1. Thus, for example, the amount of vitamin D the compositions of the various embodiments of the present invention comprising vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components, can be about 0.0004 mg to about 4 mg; about 0.4 mg to about 4 mg; about 0.004 mg to about 0.04 mg; or about 0.01 to about 1 mg.
  • The compositions of the various embodiments of the present invention comprising vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components, may be provided in any suitable form, including tablets, caplets, capsules, tablet-within-a-tablet, tablet/caplet/capsule-within-a-capsule (e.g., Duocap™ available from Capsugel Belgium NV), soft gel capsules, liquid caps (e.g., liquid filled hard capsules), sachets, powders, liquids, and the like.
  • Some embodiments of the present invention relate to unit dosages, wherein the unit dosages comprises vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components in amounts sufficient to treat or prevent diseases associated with oxidative stress. The term “unit dosage” as used generally herein refers to physically discrete units suitable as unit dosages, each unit comprising vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components in amounts (doses) sufficient to treat or prevent disease and/or condition associated with oxidative stress (e.g., CVD) or in amounts (doses) that are less than the amounts sufficient to treat or prevent a disease and/or condition associated with oxidative stress such that more than one unit dosage is necessary to provide the amounts sufficient to treat or prevent a disease and/or condition associated with oxidative stress. For example, dosage units are contemplated herein where a dosage unit provides 0.01 to 30 doses/dosage unit, e.g., 0.5 to 15 doses/dosage unit; or 1 to 5 doses/dosage unit.
  • Dosage units include, but are not limited to, tablets, caplets, capsules, tablet-within-a-tablet, tablet/caplet/capsule-within-a-capsule (e.g., Duocap™ available from Capsugel Belgium NV), soft gel capsules, liquid caps (e.g., liquid filled hard capsules) sachets, powders, and the like.
  • A dosage unit can be, e.g., a single tablet, caplet, capsule, tablet-within-a-tablet, tablet/caplet/capsule-within-a-capsule, soft gel capsules, liquid caps (e.g., liquid filled hard capsules) sachets, powder, and the like, comprising vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components. Alternatively, a dosage unit can comprise two or more tablets, caplets, capsules, tablet-within-a-tablet, tablet/caplet/capsule-within-a-capsule, soft gel capsules, liquid caps (e.g., liquid filled hard capsules) sachets, powder, and the like. For example, a dosage unit can be comprised of a tablet comprising every component but fish oil and probiotics, with the fish oil being in a capsule (or any suitable form), and the probiotics being in a powder (or any suitable form).
  • In some embodiments, compositions of the present invention comprise vitamins, minerals and trace elements, antioxidants, amino acids, and other components, but lack probiotics and fish oil. Thus, for example, a dosage unit can comprise vitamins, minerals and trace elements, antioxidants, amino acids, and other components, but lack probiotics and fish oil. The probiotics and/or fish oil can be provided separately.
  • The tablets and caplets contemplated herein may be any suitable tablets and caplets formed using compression methods know in the art, using various pharmaceutically acceptable excipients (e.g., microcrystalline cellulose, isomaltose, magnesium stearate, stearic acid, silicone dioxide, and mannitol). The tablets can also comprise surface treatments including shellac and talcum powder. In some embodiments, a single tablet or caplet can contain the vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components in amounts sufficient to treat or prevent disease and/or condition associated with oxidative stress (e.g., CVD). In various other embodiments, a plurality of tablets or caplets (e.g., two tablets, three tablets, four tablets or more) can contain one or more of the vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components, wherein the plurality of tablets or caplets (or combinations of tablets and caplets), together, comprise vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components in amounts sufficient to treat or prevent disease and/or condition associated with oxidative stress (e.g., CVD).
  • The compositions of the various embodiments of the present invention comprising vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components, may be administered daily in any suitable interval (e.g., once daily, twice daily, and three times daily). For example, the compositions may be administered one or more time daily such that the daily amounts of the compositions are sufficient to treat or prevent disease and/or condition associated with oxidative stress (e.g., CVD). In some embodiments, 1-5 doses daily are contemplated.
  • Some embodiments of the present invention relate to a kit comprising a unit dosage, wherein the unit dosage comprises vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components in amounts sufficient to treat or prevent disease and/or condition associated with oxidative stress (e.g., CVD). The kit may comprise one or more suitable containers (e.g., a pouch, plastic bag, box, and the like). In some embodiments, the kit comprises one unit dosage in a suitable container. In other embodiments, the kit comprises more than one unit dosage (e.g., two, five, ten, fifteen, twenty-five, thirty or more unit dosages) in one or more suitable containers.
  • The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those of ordinary skill in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims.
  • EXAMPLES
  • The present invention can be better understood by reference to the following examples which are offered by way of illustration. The present invention is not limited to the examples given herein.
  • Example 1
  • A composition (A) was prepared by combining the component listed in Table 2, in the amounts listed, with microcrystalline cellulose, isomaltose, magnesium stearate, stearic acid, silicone dioxide, mannitol. Six tablets can be prepared by compressing composition (A) using tableting techniques known in the art.
  • TABLE 2
    Component Preferred Amount
    Vitamin A 2.4 mg
    Vitamin B1 20 mg
    Vitamin B2 20 mg
    Vitamin B3 40 mg
    Vitamin B5 48 mg
    Vitamin B6 24 mg
    Vitamin B12 0.04 mg
    Vitamin C 480 mg
    Vitamin D 0.02 mg
    Vitamin E 200 mg
    Vitamin K 0.12 mg
    Folic Acid 0.04 mg
    Calcium 320 mg
    Potassium 600 mg
    Magnesium 200 mg
    Phosphorus 240 mg
    Iodine 0.06 mg
    Copper 2 mg
    Chromium 0.16 mg
    Manganese 20 mg
    Molybdenum 0.06 mg
    Selenium 0.2 mg
    Zinc 20 mg
    Lycopene 12 mg
    Beta-carotene 12 mg
    Citrus flavonoids 100 mg
    Biotin 0.6 mg
    Inositol 20 mg
    Choline 120 mg
  • The specific forms of certain of the component listed in Table 2 is as follows: dicalcium phosphate, potassium chloride, magnesium oxide, copper gluconate, chromium sulfate, manganese gluconate, potassium molybdate, selenomethionine, zinc lactate, extract of tomatoes/lycopene extracted from tomatoes, citrus extract, d-biotin, inositol, and choline-L-bitartarate.
  • A second composition was prepared that contained elevated vitamin D levels of 0.08 mg and cysteine, but was otherwise identical to composition (A). This second composition, composition (B), was also tableted to provide six tablets.
  • Compositions (B) was tested using a method identical to the method used to test composition (A). The testing described in this non-limiting example is also described in the Journal of Orthomolecular Medicine 26: 159-162 (2011), the entirety of which is incorporated by reference as if fully set forth herein.
  • The objective of the tests described in this non-limiting example was to determine if the compositions of various embodiments of the present invention mitigates cardiovascular disease (CVD) risk factors as determined by pulse wave velocity (PWV) and augmentation index (AIX). In the study, the patients were given the compositions described in this non-limiting example.
  • All patients were thoroughly examined and diagnosed in the ordinary medical system (i.e., the Swedish medical system) before seeking advice from an integrative medicine out-patient clinic where they were routinely tested for aortic arterial stiffness (via measuring PWV) and endothelial function (via measuring AIX) by the arteriography. Patients had many different diagnoses and were on many different types of medications. Smokers and cancer patients were excluded from participating in this study. Selected patients were offered treatment with the compositions of various embodiments of the present invention if their PWV and AIX values indicated that they were at risk of CVD. Patients were considered to be at risk for CVD when their biological age was higher than their actual age, as measured using arteriography by using values from population studies by Illyés M et al.
  • In total, 85 patients participated, their age ranging from 44-91 years, with a mean age of 67.1 years. A total of 51 females and 34 males completed treatment for two months.
  • The patients were prescribed the following treatment regimen from eight different containers, each container containing:
      • 1. Composition (A) or (B): 6 tablets/day.
      • 2. Pollen extract: 1000 mg/day from 2 g of granulate.
      • 3. Vitamin C: 2 g/day in tablet form—this is in addition to the vitamin C contained in compositions (A) and (B).
      • 4. L-arginine: 2.25 g/day.
      • 5. N-acetylcysteine: 400 mg/day.
      • 6. Fish oil: 2 g/day comprised of 35% omega-3 essential fatty acids.
      • 7. Minerals, in addition to the minerals contained in compositions (A) or (B): potassium 367 mg/day, magnesium 167 mg/day, and calcium 317 mg/day.
      • 8. Probiotic preparation: 5 mL/day containing Lactococcis lactus, Lactobacillus rhamnosus, inulin and dried powder of blueberries.
  • Assays were made of PWV and AIX using arteriography. Assay values were given as a mean of three measurements at pre-treatment time and after two months of treatment. Values are given for PWV and AIX as determined by the arteriography.
  • The results shown in Table 3 demonstrate that the compositions of various embodiments of the present invention exert a highly significant effect on PWV and AIX.
  • TABLE 3
    Before After
    Parameter Measured Treatment Treatment p-value
    PWV (m/s)* 12.0 10.0 <0.001
    PWV (biological age)*/*** 92.9 63.2 <0.001
    AIX*/** +5.2 −14.1 <0.001
    Systolic blood pressure (SBP; mm Hg) 161.4 133.0 <0.001
    Diastolic blood pressure (DBP; mm Hg) 89.6 75.2 <0.001
    Central blood pressure (cSBP; mm Hg) 150.0 122.6 <0.001
    *Calculated according to Journal of Orthomolecular Medicine 26: 159-162 (2011).
    **Value calculated from quotient between the pressure peak of the initial and the reflected wave. Percentage of patients that improved: 88.2%
    ***Calculated according to Illyés, M. et al. Budapest, Hungary.
  • Table 4 shows the results using the composition (B).
  • TABLE 4
    PWV biological
    age before/after cSBP before/after
    Patient No. treatment (years) treatment (mm Hg)
    1 98/76 148/132
    2 110/90  160/152
    3 90/78 160/142
    4 100/90  190/142
    5 72/56 142/140
    6 69/44 172/169
    7 73/27 160/123
  • As stated above, the case series involved 85 patients, aged 44-91 years (mean age=67.1 years). The male-to-female distribution was 51 females and 34 males. The compositions (A) or (B) were taken orally during two months. Included were recommended dietary intakes (RDI) of all vitamins, minerals and trace elements, except iron, and higher doses of all B vitamins, vitamin C and E, selenium and magnesium. Other nutrients that were taken orally included L-arginine, fish oil, N-acetylcysteine or cysteine, pollen extract and probiotics.
  • Measurement of cSBP, AIX, and PWV using artheriography measures the grade of arteriosclerosis and informs about three risk factors for heart infarct and stroke, namely, (i) stiffness in aorta, (ii) the function in smaller arteries, and (iii) central blood pressure. This method is considered to be the “gold standard” by European cardiovascular doctors.
  • Improvement was seen for PWV in 87.1% and for AIX in 88.2% of patients. Values for AIX decreased from +5.2 to −14.1 and for PWV from 12.0 m/s to 10.0 m/s. The values for PWV can be expressed as a decrease of the biological age of the aorta from 92.9 years to 63.2 years, i.e., a decrease of 29. 7 years (mean decrease in biological age among only the improved patients: 35.8 years). In 85 patients, the compositions of various embodiments of the present invention (e.g., compositions (A) and (B)) produced highly significant improvements in aortic PWV (i.e., aortic artery stiffness) and AIX (i.e., peripheral artery stiffness and function) in two months.
  • Studies that have evaluated nutrients in the prevention and treatment of CVD used single nutrient interventions. The results of such studies have most often been negative. The background for the approach of the present study was that the compositions of various embodiments of the present invention could afford synergistic effects if the right mix of supplements were used, and therefore prevent negative results due to incipient nutrient deficiencies.
  • The mechanisms behind the therapeutic effects induced by multiple nutrients are most certainly complex. While not wishing to be bound by any specific theory, it is believed that the addition of essential nutrients, that might be wanting, would help to restore adequate or “healthy” endothelial function. Vitamin C and other antioxidants would counteract oxidation of cholesterol moieties (e.g., low-density lipoprotein cholesterol), but also diminish free radical activity, since oxidative stress is a well-known CVD risk factor. Chronic low-grade inflammation, common to CVD, rheumatoid arthritis and other degenerative diseases, might also be counteracted by judicious nutritional supplementation.
  • In summary subjects showing elevated levels of the three risk factors showed a decrease in the biological age of aorta with 29.7 years after ingesting the compositions of various embodiments of the present invention for two months. Healthy subjects use the multi nutritional supplement at a lower dose compared to diagnosed subjects for preventing development of atherosclerosis and or other conditions and/or diseases caused by ROS and other environmental factors. The results clearly show a rejuvenation process of the vessels, not only a way of reducing the rate of aging (anti-ageing), but actually a novel and inventive method to return to a lower biological age.
  • Example 2
  • The same composition (B) described in Example 1 was prepared in tablet form using standard compression techniques according. Again, six tablets could be prepared from composition (B).
  • All patients numbering 60 were thoroughly examined and diagnosed in the ordinary medical system (i.e., the Swedish medical system). After analysis using arteriography, patients with abnormal values were offered treatment with composition (A). Smokers and cancer patients were not included. In addition, patients with any other known risk factor for CVD, such as high blood pressure, high lipids, gross over-weight, diabetes or rheumatoid arthritis, were also excluded.
  • Composition (A) was administered for two months using the same treatment regimen as in Example 1. In order to make treatment simpler and less expensive, cysteine was used instead of N-acetyl cysteine, but otherwise in the same amount. Also, it was later found that composition (A) could be combined with pollen extract, vitamin C, L-arginine, N-acetylcysteine, potassium, magnesium, and calcium to make a tablets or capsules that deliver, e.g., 1000 mg/day pollent extract, 2 g/day vitamin C, 2.25 g/day L-arginine, etc. Fish oil and the probiotic were kept separately.
  • The results from this study are shown in Table 5.
  • TABLE 5
    Before After
    Parameter Measured Treatment Treatment p-value
    PWV (m/s)* 11.6 9.4 <0.001
    PWV (biological age)*/** 86.8 53.7 <0.001
    AIX*/** +17.8 −8.3 <0.001
    SBP (mm Hg) 154.1 136.9 <0.001
    DBP (mm Hg) 89.4 82.3 <0.001
    cSBP (mm Hg) 161.0 136.2 <0.001
    DAI*** 46.7 50.8 <0.01
    *Calculated according to Journal of Orthomolecular Medicine 26: 159-162 (2011).
    **Calculated according to Illyés, M. et al. Budapest, Hungary.
    ***Indicative of perfusion of coronary arteries.
  • Analysis of arterial stiffness and function gives information on several hidden risk factors that may lay behind many cases of sudden and unexpected CVD-events. Thus, a warning can be obtained, leading to treatment and follow-up.
  • Example 3
  • The same composition (B) described in Example 1 was prepared in tablet form using standard compression techniques according. Again, six tablets could be prepared from composition (B).
  • All patients numbering 23 were thoroughly examined and diagnosed in the ordinary medical system (i.e., the Swedish medical system). After analysis using arteriography, patients with abnormal values were offered treatment with composition (A). Smokers and cancer patients were not included.
  • Composition (A) was administered for two months using the treatment regimen in Example 1. After two months, the regimen was amended to provide fewer composition (A) tablets, less than 1000 mg/day pollen extract, less than 2 g/day additional vitamin C, less than 2.25 g/day L-arginine, less than 400 mg/day N-acetylcysteine, less than 2 g/day fish oil, less than 367 mg/day potassium, less than 167 mg/day magnesium, less than 317 mg/day calcium, and less than 5 mL per day of the probiotic preparation, for an additional 34 months for a total of 36 months of treatment.
  • The results from this study are shown in Table 6.
  • TABLE 6
    Before After
    Parameter Measured Treatment Treatment p-value
    PWV (m/s)* 12.1 9.6 <0.001
    PWV (biological age)*/** 93.3 57.0 <0.001
    AIX*/** +11.5 −10.1 <0.001
    SBP (mm Hg) 157.2 139.0 <0.001
    DBP (mm Hg) 91.2 80.7 <0.001
    cSBP (mm Hg) 160.5 137.1 <0.001
    DAI*** 49.5 52 <0.01
    *Calculated according to Journal of Orthomolecular Medicine 26: 159-162 (2011).
    **Calculated according to Illyés, M. et al. Budapest, Hungary.
    ***Indicative of perfusion of coronary arteries.
  • Analysis of arterial stiffness and function gives information on several hidden risk factors that may lay behind many cases of sudden and unexpected CVD-events. Thus, a warning can be obtained, leading to treatment and follow-up. The results presented may indicate a possibility to diminish several risk factors for CVD and to maintain or even improve further this effect by using lower doses for up to three years.
  • The present invention provides for the following exemplary embodiments, the numbering of which is not to be construed as designating levels of importance:
  • Embodiment 1 relates to a method for treating or prevent a disease and/or condition associated with oxidative stress (e.g., CVD) comprising administering to a human subject (e.g., a patient in need thereof) a therapeutically effective amount of a composition comprising vitamin A, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, folic acid, calcium source, potassium source, magnesium source, phosphate source, iodine, copper source, chromium source, manganese source, molybdenum source, selenium source, zinc source, one or more tocopherols or salts thereof, lycopene, one or more carotenoids, one or more flavonoids, biotin, inositol, choline, one or more amino acids, a probiotic composition comprising the powder of one or more dried fruits and pollen extract, and fish oil.
  • Embodiment 2 relates to the method of Embodiment 1, wherein the treating comprises preventing the progression of a disease and/or condition associated with oxidative stress.
  • Embodiment 3 relates to the method of Embodiments 1-2, wherein the disease and/or condition associated with oxidative stress is selected from the group consisting of cardiovascular disease, cancer, type-2 diabetes mellitus, atherosclerosis, chronic inflammatory conditions, ischemia/reperfusion injury, sepsis, neurodegenerative diseases, Parkinson's disease, Alzheimer's disease, heart failure, myocardial infarction, schizophrenia, bipolar disorder, fragile X syndrome, sickle cell disease, lichen planus, vitiligo, autism, chronic fatigue syndrome, and combinations thereof.
  • Embodiment 4 relates to the method of Embodiment 1-3 wherein the disease and/or condition associated with oxidative stress is cardiovascular disease.
  • Embodiment 5 relates to the method of Embodiment 4, wherein the cardiovascular disease is at least one of atherosclerosis, heart infarct, and stroke.
  • Embodiment 6 relates to the method of Embodiments 1-5, wherein the composition comprises vitamin A (0.01-10 mg), vitamin B1 (1-50 mg), vitamin B2 (1-50 mg), vitamin B3 (1-100 mg), vitamin B5 (1-100 mg), vitamin B6 (0.5-50 mg), vitaminB12 (0.0001-2 mg), vitamin C (0.1-1000 mg), vitamin D (0.0001-1 mg), vitamin E (1-500 mg), vitamin K (0.001-5 mg), folic acid (0.0001-5 mg), calcium source (0.1-1000 mg), potassium source (0.1-1000 mg), magnesium source (0.1-1000 mg), phosphate source (1-500 mg), iodine source (0.0001-5 mg), copper source (0.0001-10 mg), chromium source (0.0001-10 mg), manganese source (0.0001-50 mg), molybdenum source (0.0001-10 mg), selenium source (0.0001-10 mg), zinc source (0.001-50 mg), lycopene (0.0001-20 mg), one or more carotenoids (0.0001-20 mg), one or more flavonoids (1-500 mg), biotin (0.0001-20 mg), inositol (0.001-100 mg), choline (0.0001-500 mg), one or more amino acids (0.0001-100 g), a probiotic composition (1-10 mL) comprising the powder of one or more dried fruits (0.0001-2000 mg) and pollen extract (1-10,000 mg), and fish oil (0.0001-20 g).
  • Embodiment 7 relates to the method of Embodiments 1-6, wherein the composition comprises an additional amount of vitamin D such that the total amount of vitamin D is 0.0004-4 mg vitamin D.
  • Embodiment 8 relates to the method of Embodiments 1-7, wherein the composition comprises an additional amount of at least one of vitamin C, a potassium source, a magnesium source, and a calcium source.
  • Embodiment 9 relates to the method of Embodiments 1-8, wherein the probiotic composition comprises lactic acid bacteria or cultures thereof (e.g., Lactococcis lactus culture, Lactobacillus rhamnosus culture, and combinations thereof), inulin, and dried powder of blueberries.
  • Embodiment 10 relates to the method of Embodiments 1-9, wherein the composition comprises vitamin A, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, folic acid, potassium chloride, magnesium oxide, dicalcium phosphate, iodine, copper gluconate, chromium sulfate, manganese gluconate, potassium molybdate, selenomethionine, zinc lactate, d-alpha-tocopherol acetate, lycopene, beta-carotene, citrus flavonoids, L-cysteine or N-acetyl cysteine, L-arginine, a probiotic composition comprising dried powder of blueberries and pollen extract, d-biotin, inositol, choline-L-bitartarate, and fish oil.
  • Embodiment 11 relates to a method of delaying or preventing the onset of a disease and/or condition associated with oxidative stress comprising administering to a human subject (e.g., a patient in need thereof) a therapeutically effective amount of a composition comprising vitamin A, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, folic acid, calcium source, potassium source, magnesium source, phosphate source, iodine, copper source, chromium source, manganese source, molybdenum source, selenium source, zinc source, lycopene, one or more carotenoids, one or more flavonoids, biotin, inositol, choline, one or more amino acids, a probiotic composition comprising the powder of one or more dried fruits and pollen extract, and fish oil.
  • Embodiment 12 relates to a composition comprising:
      • (i) vitamin A, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, folic acid, calcium source, potassium source, magnesium source, phosphate source, iodine, copper source, chromium source, manganese source, molybdenum source, selenium source, zinc source, lycopene, one or more carotenoids, one or more flavonoids, biotin, inositol, choline, one or more amino acids,
      • (ii) a probiotic composition comprising the powder of one or more dried fruits and pollen extract,
      • (iii) fish oil, and
      • (iv) one or more pharmaceutically acceptable excipients.
  • Embodiment 13 relates to the composition of Embodiment 12, wherein the composition is in the form of a tablet, powder, liquid, capsule or combinations thereof.
  • Embodiment 14 relates to the composition of Embodiments 12-13, wherein components (i) and (iv) are comprised in the same dosage unit, separate from the probiotic composition and the fish oil.
  • Embodiment 15 relates to the composition of Embodiments 12-14, wherein the dosage unit is one or more tablets, caplets, capsules, tablet-within-a-tablet, tablet/caplet/capsule-within-a-capsule, soft gel capsules, liquid caps or sachets.
  • Embodiment 16 relates to the composition of Embodiments 12-15, wherein the composition comprises vitamin A (0.01-10 mg), vitamin B1 (1-50 mg), vitamin B2 (1-50 mg), vitamin B3 (1-100 mg), vitamin B5 (1-100 mg), vitamin B6 (0.5-50 mg), vitamin B12 (0.0001-2 mg), vitamin C (0.1-1000 mg), vitamin D (0.0001-1 mg), vitamin E (1-500 mg), vitamin K (0.001-5 mg), folic acid (0.0001-5 mg), calcium source (0.1-1000 mg), potassium source (0.1-1000 mg), magnesium source (0.1-1000 mg), phosphate source (1-500 mg), iodine source (0.0001-5 mg), copper source (0.0001-10 mg), chromium source (0.0001-10 mg), manganese source (0.0001-50 mg), molybdenum source (0.0001-10 mg), selenium source (0.0001-10 mg), zinc source (0.001-50 mg), lycopene (0.0001-20 mg), one or more carotenoids (0.0001-20 mg), one or more flavonoids (1-500 mg), biotin (0.0001-20 mg), inositol (0.001-100 mg), choline (0.0001-500 mg), one or more amino acids (0.0001-100 g), a probiotic composition (1-10 mL) comprising the powder of one or more dried fruits (0.0001-2000 mg) and pollen extract (1-10,000 mg), and fish oil (0.0001-20 g).
  • Embodiment 17 relates to the composition of Embodiments 12-16, wherein the composition comprises an additional amount of vitamin D such that the total amount of vitamin D is 0.0004-4 mg vitamin D.
  • Embodiment 18 relates to the composition of Embodiments 12-17, wherein the composition comprises an additional amount of at least one of vitamin C, a potassium source, a magnesium source, and a calcium source.
  • Embodiment 19 relates to the composition of Embodiments 12-18, wherein the probiotic composition comprises lactic acid bacteria or cultures thereof (e.g., Lactococcis lactus culture, Lactobacillus rhamnosus culture, and combinations thereof), inulin, and dried powder of blueberries.
  • Embodiment 20 relates to the composition of Embodiments 12-19, wherein the composition comprises vitamin A, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, folic acid, potassium chloride, magnesium oxide, dicalcium phosphate, iodine, copper gluconate, chromium sulfate, manganese gluconate, potassium molybdate, selenomethionine, zinc lactate, lycopene, beta-carotene, citrus flavonoids, L-cysteine or N-acetyl cysteine, L-arginine, a probiotic composition comprising dried powder of blueberries and pollen extract, d-biotin, inositol, choline-L-bitartarate, and fish oil.
  • Embodiment 21 relates to a kit comprising the composition of claims 13-20 in a suitable container.
  • Embodiment 22 relates to the kit of Embodiment 21, wherein the composition is comprised in a dosage unit.
  • Embodiment 23 relates to the kit of Embodiment 22, wherein the dosage unit is one or more tablets, caplets, capsules, tablet-within-a-tablet, tablet/caplet/capsule-within-a-capsule, soft gel capsules, liquid caps or sachets.
  • Embodiment 24 relates to the kit of Embodiments 21-23, wherein the composition comprises vitamin A, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, folic acid, potassium chloride, magnesium oxide, dicalcium phosphate, iodine, copper gluconate, chromium sulfate, manganese gluconate, potassium molybdate, selenomethionine, zinc lactate, lycopene, beta-carotene, citrus flavonoids, L-cysteine or N-acetyl cysteine, L-arginine, a probiotic composition comprising dried powder of blueberries and pollen extract, d-biotin, inositol, choline-L-bitartarate, and fish oil in amounts sufficient to treat or prevent a disease and/or condition associated with oxidative stress.

Claims (26)

What is claimed is:
1. A method for treating or prevent a disease and/or condition associated with oxidative stress comprising administering to a human subject a therapeutically effective amount of a composition comprising vitamin A, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, folic acid, calcium source, potassium source, magnesium source, phosphate source, iodine, copper source, chromium source, manganese source, molybdenum source, selenium source, zinc source, one or more tocopherols or salts thereof, lycopene, one or more carotenoids, one or more flavonoids, biotin, inositol, choline, one or more amino acids, a probiotic composition comprising the powder of one or more dried fruits and pollen extract, and fish oil.
2. The method of claim 1, wherein the treating comprises preventing the progression of a disease and/or condition associated with oxidative stress.
3. The method of claim 1, wherein the disease and/or condition associated with oxidative stress is selected from the group consisting of cardiovascular disease, cancer, type-2 diabetes mellitus, atherosclerosis, chronic inflammatory conditions, ischemia/reperfusion injury, sepsis, neurodegenerative diseases, Parkinson's disease, Alzheimer's disease, heart failure, myocardial infarction, schizophrenia, bipolar disorder, fragile X syndrome, sickle cell disease, lichen planus, vitiligo, autism, chronic fatigue syndrome, and combinations thereof.
4. The method of claim 3, wherein the disease and/or condition associated with oxidative stress is cardiovascular disease.
5. The method of claim 4, wherein the cardiovascular disease is at least one of atherosclerosis, heart infarct, and stroke.
6. The method of claim 1, wherein the composition comprises vitamin A (0.01-10 mg), vitamin B1 (1-50 mg), vitamin B2 (1-50 mg), vitamin B3 (1-100 mg), vitamin B5 (1-100 mg), vitamin B6 (0.5-50 mg), vitamin B12 (0.0001-2 mg), vitamin C (0.1-1000 mg), vitamin D (0.0001-1 mg), vitamin E (1-500 mg), vitamin K (0.001-5 mg), folic acid (0.0001-5 mg), calcium source (0.1-1000 mg), potassium source (0.1-1000 mg), magnesium source (0.1-1000 mg), phosphate source (1-500 mg), iodine source (0.0001-5 mg), copper source (0.0001-10 mg), chromium source (0.0001-10 mg), manganese source (0.0001-50 mg), molybdenum source (0.0001-10 mg), selenium source (0.0001-10 mg), zinc source (0.001-50 mg), lycopene (0.0001-20 mg), one or more carotenoids (0.0001-20 mg), one or more flavonoids (1-500 mg), biotin (0.0001-20 mg), inositol (0.001-100 mg), choline (0.0001-500 mg), one or more amino acids (0.0001-100 g), a probiotic composition (1-10 mL) comprising the powder of one or more dried fruits (0.0001-2000 mg) and pollen extract (1-10,000 mg), and fish oil (0.0001-20 g).
7. The method of claim 6, wherein the composition comprises an additional amount of vitamin D such that the total amount of vitamin D is 0.0004-4 mg vitamin D.
8. The composition of claim 6, wherein the composition comprises an additional amount of at least one of vitamin C, a potassium source, a magnesium source, and a calcium source.
9. The method of claim 1, wherein the probiotic composition comprises at least one lactic acid bacterium or a culture thereof, inulin, and dried powder of blueberries.
10. The method of claim 9, wherein the at least one lactic acid bacterium comprises Lactococcis lactus, Lactobacillus rhamnosus, or cultures and combinations thereof.
11. The method of claim 1, wherein the composition comprises vitamin A, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, folic acid, potassium chloride, magnesium oxide, dicalcium phosphate, iodine, copper gluconate, chromium sulfate, manganese gluconate, potassium molybdate, selenomethionine, zinc lactate, d-alpha-tocopherol acetate, lycopene, beta-carotene, citrus flavonoids, L-cysteine or N-acetyl cysteine, L-arginine, a probiotic composition comprising dried powder of blueberries and pollen extract, d-biotin, inositol, choline-L-bitartarate, and fish oil.
12. A method of delaying or preventing the onset of a disease and/or condition associated with oxidative stress comprising administering to a human subject a therapeutically effective amount of a composition comprising vitamin A, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, folic acid, calcium source, potassium source, magnesium source, phosphate source, iodine, copper source, chromium source, manganese source, molybdenum source, selenium source, zinc source, lycopene, one or more carotenoids, one or more flavonoids, biotin, inositol, choline, one or more amino acids, a probiotic composition comprising the powder of one or more dried fruits and pollen extract, and fish oil.
13. A composition comprising:
(v) vitamin A, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, folic acid, calcium source, potassium source, magnesium source, phosphate source, iodine, copper source, chromium source, manganese source, molybdenum source, selenium source, zinc source, lycopene, one or more carotenoids, one or more flavonoids, biotin, inositol, choline, one or more amino acids,
(vi) a probiotic composition comprising the powder of one or more dried fruits and pollen extract,
(vii) fish oil, and
(viii) one or more pharmaceutically acceptable excipients.
14. The composition of claim 13, wherein the composition is in the form of a tablet, powder, liquid, capsule or combinations thereof.
15. The composition of claim 13, wherein components (i) and (iv) are comprised in the same dosage unit, separate from the probiotic composition and the fish oil.
16. The composition of claim 13, wherein the dosage unit is one or more tablets, caplets, capsules, tablet-within-a-tablet, tablet/caplet/capsule-within-a-capsule, soft gel capsules, liquid caps or sachets.
17. The composition of claim 13, wherein the composition comprises vitamin A (0.01-10 mg), vitamin B1 (1-50 mg), vitamin B2 (1-50 mg), vitamin B3 (1-100 mg), vitamin B5 (1-100 mg), vitamin B6 (0.5-50 mg), vitamin B12 (0.0001-2 mg), vitamin C (0.1-1000 mg), vitamin D (0.0001-1 mg), vitamin E (1-500 mg), vitamin K (0.001-5 mg), folic acid (0.0001-5 mg), calcium source (0.1-1000 mg), potassium source (0.1-1000 mg), magnesium source (0.1-1000 mg), phosphate source (1-500 mg), iodine source (0.0001-5 mg), copper source (0.0001-10 mg), chromium source (0.0001-10 mg), manganese source (0.0001-50 mg), molybdenum source (0.0001-10 mg), selenium source (0.0001-10 mg), zinc source (0.001-50 mg), lycopene (0.0001-20 mg), one or more carotenoids (0.0001-20 mg), one or more flavonoids (1-500 mg), biotin (0.0001-20 mg), inositol (0.001-100 mg), choline (0.0001-500 mg), one or more amino acids (0.0001-100 g), a probiotic composition (1-10 mL) comprising the powder of one or more dried fruits (0.0001-2000 mg) and pollen extract (1-10,000 mg), and fish oil (0.0001-20 g).
18. The composition of claim 13, wherein the composition comprises an additional amount of vitamin D such that the total amount of vitamin D is 0.0004-4 mg vitamin D.
19. The composition of claim 13, wherein the composition comprises an additional amount of at least one of vitamin C, a potassium source, a magnesium source, and a calcium source.
20. The composition of claim 13, wherein the probiotic composition comprises at least one lactic acid bacterium or a culture thereof, inulin, and dried powder of blueberries.
21. The composition of claim 20, wherein the at least one lactic acid bacterium comprises Lactococcis lactus, Lactobacillus rhamnosus, or cultures and combinations thereof.
22. The composition of claim 13, wherein the composition comprises vitamin A, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, folic acid, potassium chloride, magnesium oxide, dicalcium phosphate, iodine, copper gluconate, chromium sulfate, manganese gluconate, potassium molybdate, selenomethionine, zinc lactate, lycopene, beta-carotene, citrus flavonoids, L-cysteine or N-acetyl cysteine, L-arginine, a probiotic composition comprising dried powder of blueberries and pollen extract, d-biotin, inositol, choline-L-bitartarate, and fish oil.
23. A kit comprising the composition of claim 13 in a suitable container.
24. The kit of claim 23, wherein the composition is comprised in a dosage unit.
25. The kit of claim 24, wherein the dosage unit is one or more tablets, caplets, capsules, tablet-within-a-tablet, tablet/caplet/capsule-within-a-capsule, soft gel capsules, liquid caps or sachets.
26. The kit of claim 23, wherein the composition comprises vitamin A, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, folic acid, potassium chloride, magnesium oxide, dicalcium phosphate, iodine, copper gluconate, chromium sulfate, manganese gluconate, potassium molybdate, selenomethionine, zinc lactate, lycopene, beta-carotene, citrus flavonoids, L-cysteine or N-acetyl cysteine, L-arginine, a probiotic composition comprising dried powder of blueberries and pollen extract, d-biotin, inositol, choline-L-bitartarate, and fish oil in amounts sufficient to treat or prevent a disease and/or condition associated with oxidative stress.
US14/104,940 2012-12-12 2013-12-12 Multi-nutrient supplement and uses thereof Abandoned US20140161878A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US14/104,940 US20140161878A1 (en) 2012-12-12 2013-12-12 Multi-nutrient supplement and uses thereof
US16/389,326 US11590190B2 (en) 2012-12-12 2019-04-19 Multi-nutrient supplement and uses thereof
US17/379,255 US11963992B2 (en) 2012-12-12 2021-07-19 Multi-nutrient supplement composition and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261736215P 2012-12-12 2012-12-12
US14/104,940 US20140161878A1 (en) 2012-12-12 2013-12-12 Multi-nutrient supplement and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/389,326 Division US11590190B2 (en) 2012-12-12 2019-04-19 Multi-nutrient supplement and uses thereof

Publications (1)

Publication Number Publication Date
US20140161878A1 true US20140161878A1 (en) 2014-06-12

Family

ID=50881193

Family Applications (3)

Application Number Title Priority Date Filing Date
US14/104,940 Abandoned US20140161878A1 (en) 2012-12-12 2013-12-12 Multi-nutrient supplement and uses thereof
US16/389,326 Active 2035-05-08 US11590190B2 (en) 2012-12-12 2019-04-19 Multi-nutrient supplement and uses thereof
US17/379,255 Active 2033-12-26 US11963992B2 (en) 2012-12-12 2021-07-19 Multi-nutrient supplement composition and uses thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
US16/389,326 Active 2035-05-08 US11590190B2 (en) 2012-12-12 2019-04-19 Multi-nutrient supplement and uses thereof
US17/379,255 Active 2033-12-26 US11963992B2 (en) 2012-12-12 2021-07-19 Multi-nutrient supplement composition and uses thereof

Country Status (1)

Country Link
US (3) US20140161878A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3017029A1 (en) * 2014-01-31 2015-08-07 Nutra Canada ACTIVE NUTRITIONAL PRINCIPLE OBTAINED FROM ANGUSTIFOLIUM VACCINE, COMPOSITION CONTAINING THE SAME AND USE THEREOF
WO2016020487A1 (en) * 2014-08-08 2016-02-11 Nestec S.A. Vitamin b2 and its use
WO2016020489A1 (en) * 2014-08-08 2016-02-11 Nestec S.A. Vitamin b2 for gestational diabetes
US20170056381A1 (en) * 2014-02-20 2017-03-02 Nanometics Llc Pyridoxamine for the treatment of sickle cell disease, thalassemia and related blood diseases
US20220277828A1 (en) * 2021-03-01 2022-09-01 Kpn Innovations, Llc. Methods and systems for reversing a geriatric process
US11590190B2 (en) 2012-12-12 2023-02-28 Sweet Wellness AB Multi-nutrient supplement and uses thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110916192B (en) * 2019-11-25 2021-04-13 垒途智能教科技术研究院江苏有限公司 Probiotic mineral powder capable of preventing and treating autism of children and teenagers and application thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4326523A (en) * 1980-08-25 1982-04-27 International Minerals & Chemical Corp. Method of supplying micronutrients to animals
US4740373A (en) * 1986-05-27 1988-04-26 Usv Pharmaceutical Corporation Stabilization of multivitamin/trace elements formulations
US5514382A (en) * 1994-10-17 1996-05-07 Sultenfuss; Sherry Daily vitamin and mineral supplement for women
US5848443A (en) * 1997-12-08 1998-12-15 Waugh; Aston Portable automobile urinal
US6299896B1 (en) * 2000-04-13 2001-10-09 Cooper Concepts, Inc. Multi-vitamin and mineral supplement
US20040001817A1 (en) * 2002-05-14 2004-01-01 Giampapa Vincent C. Anti-aging nutritional supplement
US20100291050A1 (en) * 2009-05-14 2010-11-18 Daikeler Carl D Nutritional Compositions for Reducing Oxidative Damage

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948443A (en) * 1996-02-23 1999-09-07 Medical Doctor's Research Institute, Inc. Acetylsalicylic acid and micronutrient supplementation for nutritional losses and coronary heart disease
US6048846A (en) 1998-02-26 2000-04-11 Cochran; Timothy M. Compositions used in human treatment
US20030007961A1 (en) 2001-06-22 2003-01-09 Wilburn Michael D. Orthomolecular vitamin E derivatives
US7368481B1 (en) 2002-09-27 2008-05-06 Rapisarda Family Irrevocable Trust Pet anti-aging wellness supplement for cats
WO2004095926A2 (en) 2003-04-28 2004-11-11 Monsanto Technology, Llc Treatment of plants and plant propagation materials with an antioxidant to improve plant health and/or yield
US20050079247A1 (en) 2003-10-14 2005-04-14 Slilaty George E. Food composition and method of making same
US20060115556A1 (en) 2004-12-01 2006-06-01 Foulger Sidney W Nutritional supplement drink containing xanthone extracts
US20060115555A1 (en) 2004-12-01 2006-06-01 Foulger Sidney W Nutritional supplements containing xanthone extracts
US20080038367A1 (en) 2006-08-11 2008-02-14 Sal Saloum Nutritional supplement compositions and methods of preparing
US20080305096A1 (en) 2007-06-07 2008-12-11 Unicity International, Inc. Method and composition for providing controlled delivery of biologically active substances
US20140161878A1 (en) 2012-12-12 2014-06-12 Sweet Wellness AB Multi-nutrient supplement and uses thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4326523A (en) * 1980-08-25 1982-04-27 International Minerals & Chemical Corp. Method of supplying micronutrients to animals
US4740373A (en) * 1986-05-27 1988-04-26 Usv Pharmaceutical Corporation Stabilization of multivitamin/trace elements formulations
US5514382A (en) * 1994-10-17 1996-05-07 Sultenfuss; Sherry Daily vitamin and mineral supplement for women
US5848443A (en) * 1997-12-08 1998-12-15 Waugh; Aston Portable automobile urinal
US6299896B1 (en) * 2000-04-13 2001-10-09 Cooper Concepts, Inc. Multi-vitamin and mineral supplement
US20040001817A1 (en) * 2002-05-14 2004-01-01 Giampapa Vincent C. Anti-aging nutritional supplement
US20100291050A1 (en) * 2009-05-14 2010-11-18 Daikeler Carl D Nutritional Compositions for Reducing Oxidative Damage

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
American Heritage Dictionary of the English Language, Fifth Edition (http://www.thefreedictionary.com/taurine; page 1, accessed 12/27/2016) *
Cambridge Dictionary (http://dictionary.cambridge.org/us/dictionary/english/taurine; page 1, accessed 12/27/2016) *
Huys (Research in Microbiology 157 (2006) 803-810) *
Kimoto (Letters in Applied Microbiology 1999, 29, 313-316) *
Kris-Atherton (Circulation. 2002;106:2747-2757) *
Lourens-Hattingh (International Dairy Journal 11 (2001) 1-17) *
Mosby’s Dictionary of Complementary and Alternative Medicine (http://medical-dictionary.thefreedictionary.com/taurine; page 2, accessed 12/27/2016) *
NIH1 (http://ods.od.nih.gov/pdf/factsheets/VitaminD-HealthProfessional.pdf; accessed 11/7/2014) *
NIH2 (http://dietarysupplementdatabase.usda.nih.gov/faq.html, accessed 11/7/2014) *
Oxford English Dictionary (https://en.oxforddictionaries.com/definition/taurine; page 1, accessed 12/27/2016) *
ProJoba (http://www.youngevity.net/product/PJ520.html; 10/17/2012) *
Saunders Comprehensive Veterinary Dictionary (http://medical-dictionary.thefreedictionary.com/taurine; page 1, accessed 12/27/2016) *
Sloan (http://www.mskcc.org/cancer-care/herb/quercetin; accessed 11/7/2014) *
Verdenelli (Eur J Nutr (2009) 48:355-363) *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11590190B2 (en) 2012-12-12 2023-02-28 Sweet Wellness AB Multi-nutrient supplement and uses thereof
US11963992B2 (en) 2012-12-12 2024-04-23 Scandinavian Good Business AB Multi-nutrient supplement composition and uses thereof
FR3017029A1 (en) * 2014-01-31 2015-08-07 Nutra Canada ACTIVE NUTRITIONAL PRINCIPLE OBTAINED FROM ANGUSTIFOLIUM VACCINE, COMPOSITION CONTAINING THE SAME AND USE THEREOF
US20170056381A1 (en) * 2014-02-20 2017-03-02 Nanometics Llc Pyridoxamine for the treatment of sickle cell disease, thalassemia and related blood diseases
WO2016020487A1 (en) * 2014-08-08 2016-02-11 Nestec S.A. Vitamin b2 and its use
WO2016020489A1 (en) * 2014-08-08 2016-02-11 Nestec S.A. Vitamin b2 for gestational diabetes
CN107073004A (en) * 2014-08-08 2017-08-18 雀巢产品技术援助有限公司 Vitamin B2 and application thereof
EP3598902A1 (en) * 2014-08-08 2020-01-29 Société des Produits Nestlé S.A. Vitamin b2 and its use
EP3718418A1 (en) * 2014-08-08 2020-10-07 Société des Produits Nestlé S.A. Vitamin b2 and myo-inositol for treating and preventing gestational diabetes
US20220277828A1 (en) * 2021-03-01 2022-09-01 Kpn Innovations, Llc. Methods and systems for reversing a geriatric process

Also Published As

Publication number Publication date
US11963992B2 (en) 2024-04-23
US11590190B2 (en) 2023-02-28
US20220008498A1 (en) 2022-01-13
US20190282647A1 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
US11963992B2 (en) Multi-nutrient supplement composition and uses thereof
Vitamin Fact sheet for health professionals
El Sohaimy Functional foods and nutraceuticals-modern approach to food science
US6270774B1 (en) Nutritional supplement composition and use
KR101262686B1 (en) Composition for body fat reduction
KR20190007412A (en) And compositions for improving weight loss and cardiovascular health after eating and exercise
Sirtori et al. Nutraceuticals for blood pressure control
AU2016375177A1 (en) Compositions comprising nicotinamide riboside and a urolithin
WO2010132822A1 (en) Nutritional compositions for reducing oxidative damage
JP7367978B2 (en) Composition
US20210393657A1 (en) Synthetic composition for preventing or treating cvd
KR20180094517A (en) Garlic composition
WO2015105437A1 (en) Multi nutrient supplementation
US20160106695A1 (en) Petroselinic acid or a combination of active ingredients comprising at least petroselinic acid for promoting weight loss and/or weight maintenance
EP3135281B1 (en) Composition for preventing or improving peripheral neuropathy
JP2007126399A (en) Composition for increasing glutathione
JP4818637B2 (en) Low density lipoprotein (LDL) oxidation inhibitor
KR20120082196A (en) Functional food compositions having the recovery effect of blood composition and function
Niknamian Introducing the Sorush Cancer Treatment Protocol (SCTP)
Mason Potential uses for coenzyme Q10
JP2012067041A (en) Ace activity inhibitor
Al-Okbi et al. Urgent Need of Nutritional Strategy and Innovated Functional Foods for Athletes Health and Fitness
Zhivikj et al. Toxicity of food supplements as an adjuvant for COVID-19 treatment or prevention
Ritu et al. Impact of intervention with Co-Enzyme Q10 on homocysteine levels of cardiac patients with established angiographic evidence
Qin Dietary Supplements

Legal Events

Date Code Title Description
STCV Information on status: appeal procedure

Free format text: BOARD OF APPEALS DECISION RENDERED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION